Natera wins Medicare coverage for colorectal cancer test

By LabPulse.com staff writers

September 3, 2020 -- Natera has received local coverage determination (LCD) from the U.S. Centers for Medicare and Medicaid Services for serial use of the Signatera molecular residual disease test in patients with colorectal cancer.

The LCD will be effective beginning on October 18, 2020, and applies to Medicare beneficiaries with current or prior stage II or stage III colorectal cancer. The future-effective coverage is consistent with Medicare's draft released in August 2019, the company noted.

The LCD coverage includes risk stratification of patients after surgical resection in order to make adjuvant treatment decisions. It also allows for recurrence monitoring for patients in remission with the same frequency as carcinoembryonic antigen (CEA) testing.

This is the first covered indication for Signatera, according to Natera staff. The company noted that the diagnostic can detect multiple types of residual cancer up to two years earlier than standard tests.

Natera to collaborate with MGH on breast cancer trial
Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in...
Natera touts data supporting personalized ctDNA testing
Natera is highlighting clinical data that supports the efficacy of personalized circulating tumor DNA (ctDNA) testing for oligometastatic colorectal cancer.
Natera files patent lawsuit against Progenity
Natera has filed a lawsuit against Progenity for infringing six U.S. patents.
New technique improves Natera's organ transplant test
Natera has launched a new technique that enhances results from Prospera, the company's donor-derived cell-free DNA organ transplant laboratory-developed...
Natera's prenatal testing coverage expands
A national insurer has expanded coverage of Natera's Panorama cell-free DNA and noninvasive prenatal test to all pregnant women, regardless of age. Natera...

Copyright © 2020 LabPulse.com

Last Updated np 9/4/2020 2:46:10 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email